Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates
CHRS•Outlook
- Company expects initial data readouts from multiple clinical trials in 2H 2026
- Company projects public disclosure of mature data sets in October 2026
- A new Phase 1b study in prostate cancer is expected to begin in fall 2026
Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the pharmaceuticals peer group is "buy"
- Wall Street's median 12-month price target for Coherus Oncology Inc is $6.50, about 339.2% above its August 4 closing price of $1.48
Related Reuters reads
- Aug. 4 - Merck posts better-than-expected second-quarter results on Keytruda strength
- Aug. 4 - Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
- Aug. 5 - Black Diamond Therapeutics Q2 net loss narrows year over year
Q2 results and revenue drivers
Coherus Oncology's second-quarter revenue rose 40% year over year, but slightly missed analyst expectations.
- U.S. oncology therapeutics firm's Q2 revenue up 40% yr/yr, slight miss vs analyst expectations
